News EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023 Staff September 11, 2023 Iframe sync Post Navigation Previous Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive OfficerNext Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer More Stories Healthcare News Pharmaceutical Define Ventures Appoints Carolyn Magill as Venture Partner Staff March 11, 2025 Healthcare News So-Young to Report Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 Staff March 11, 2025 News Robotics AMI and congatec Celebrate 20 Years of Successful Partnership Staff March 11, 2025
